What is the primary indication for sympathomimetic bronchodilators?

What is the primary indication for sympathomimetic bronchodilators?

• A. To reduce blood pressure
• B. To relax bronchial smooth muscle
• C. To decrease heart rate
• D. To treat infections

Answer: (B)

The primary indication for sympathomimetic bronchodilators is to relax bronchial smooth muscle. These medications stimulate beta-adrenergic receptors in the airway, leading to dilation of the bronchial passages. This relaxation of the smooth muscle helps to improve airflow and relieve symptoms of bronchoconstriction associated with conditions like asthma and chronic obstructive pulmonary disease (COPD). In contrast, reducing blood pressure is not a primary function of these bronchodilators, as their main role is focused on the respiratory system rather than cardiovascular effects. Additionally, while some sympathomimetic agents can impact heart rate by stimulating beta-adrenergic receptors in the heart, their primary focus in this context is on bronchodilation rather than decreasing heart rate. Lastly, treating infections does not involve bronchodilation therapy; instead, it typically requires antibiotic or antiviral medications. Therefore, the correct answer highlights the specific therapeutic action of sympathomimetic bronchodilators in relaxing airway smooth muscle, which directly addresses respiratory distress and obstruction.

The primary indication for sympathomimetic bronchodilators is to relax bronchial smooth muscle. These medications stimulate beta-adrenergic receptors in the airway, leading to dilation of the bronchial passages. This relaxation of the smooth muscle helps to improve airflow and relieve symptoms of bronchoconstriction associated with conditions like asthma and chronic obstructive pulmonary disease (COPD).

In contrast, reducing blood pressure is not a primary function of these bronchodilators, as their main role is focused on the respiratory system rather than cardiovascular effects. Additionally, while some sympathomimetic agents can impact heart rate by stimulating beta-adrenergic receptors in the heart, their primary focus in this context is on bronchodilation rather than decreasing heart rate. Lastly, treating infections does not involve bronchodilation therapy; instead, it typically requires antibiotic or antiviral medications. Therefore, the correct answer highlights the specific therapeutic action of sympathomimetic bronchodilators in relaxing airway smooth muscle, which directly addresses respiratory distress and obstruction.